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Background: Elevated interleukin-6 (IL-6) and complement activation are associated
with detrimental effects of inflammation in coronary artery disease (CAD). The
complement anaphylatoxins C5a and C3a interact with their receptors; the highly
inflammatory C5aR1, and the C5aR2 and C3aR. We evaluated the effect of the
IL-6 receptor (IL-6R)-antagonist tocilizumab on the expression of the anaphylatoxin
receptors in whole blood from non-ST-elevation myocardial infarction (NSTEMI) patients.
Separately, anaphylatoxin receptor expression in peripheral blood mononuclear cells
(PBMC) from patients with different entities of CAD was investigated.
Materials andMethods: NSTEMI patients were randomized to one dose of tocilizumab
(n = 28) or placebo (n = 32) and observed for 6 months. Whole blood samples
drawn at inclusion, at day 2, 3 and after 6 months were used for mRNA isolation.
Plasma was prepared for analysis of complement activation measured as sC5b-9
by ELISA. Furthermore, patients with different CAD entities comprising stable angina
pectoris (SAP, n = 22), non-ST-elevation acute coronary syndrome (NSTE-ACS, n = 21)
and ST-elevation myocardial infarction (STEMI, n = 20) were included. PBMC was
isolated from blood samples obtained at admission to hospital and mRNA isolated.
Anaphylatoxin-receptor-expression was analyzed with qPCR using mRNA from whole
blood and PBMC, respectively.
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Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA
expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas
C3aR expression was unaffected. (ii) Tocilizumab did not affect complement activation.
(iii) In analyzes of different CAD entities, C5aR1 expression was significantly increased
in all CAD subgroups compared to controls with the highest level in the STEMI patients
(p < 0.001). For C5aR2 and C3aR the expression compared to controls were more
moderate with increased expression of C5aR2 in the STEMI group (p < 0.05) and C3aR
in the NSTE-ACS group (p < 0.05).
Conclusion: Expression of C5aR1 and C5aR2 in whole blood was significantly
attenuated by IL-6R-inhibition in NSTEMI patients. These receptors were significantly
upregulated in PBMC CAD patients with particularly high levels of C5aR1 in STEMI
patients.
Keywords: complement, C5a receptors, C3a receptor, IL-6, myocardial infarction, inflammation
INTRODUCTION
Inflammation plays a pivotal role in the pathophysiology of
coronary artery disease (CAD) from the establishment of the
atherosclerotic plaque through rupture or erosion of the plaque
leading to partial or total occlusion of the coronary vessel. This
might lead to myocardial necrosis and thereby a myocardial
infarction (MI). A total occlusion typically leads to ST-elevation
in the electrocardiogram whereas a partial occlusion or an
occlusion with collateral circulation doses not show these changes
and are classified as unstable coronary syndromes. Unstable
coronary syndromes with elevated levels of Troponin T, a marker
of myocardial necrosis, are classified as non-ST-elevation MI
(non-STEMI) whereas without rice in TnT are classified as non-
ST-elevation acute coronary syndromes (1). Rapid restoration
of coronary blood flow by re-opening of the occluded coronary
vessel with percutaneous coronary intervention (PCI), has
considerably improved outcome following MI. However, CAD is
still associated with considerable morbidity and mortality (2).
Both the myocardial necrosis and the reperfusion of
the infarcted myocardium activate inflammatory mechanisms.
Innate and adaptive immune mechanisms are involved in this
process and act together to orchestrate a response to damage
(3). A balanced inflammatory response is required for proper
healing following myocardial infarction (MI), whereas excessive
inflammation could give rise to collateral tissue damage with
detrimental effects on the myocardium (4). The complement
system is an important sensor and effector system of innate
immunity and plays a role in all phases of CAD (5). The
complement system exerts its main inflammatory functions
through proteolytic activation of C3 and C5, which upon
cleavage liberate the complement anaphylatoxins C5a and C3a.
The anaphylatoxins bind to their respective receptors: the
C5a receptor 1 and 2 (C5aR1, C5aR2) and the C3a receptor
(C3aR) (6), and the C5a-C5aR1-axis seems to be involved in
atherogenesis and CAD (7–9). C5aR inherits an inflammatory
role following tissue injury stimulating the release of cytokines
like tumor necrosis factor (TNF), interleukin (IL)-1β, IL-6, and
chemokines, e.g., IL-8 (10), and induce thrombogenicity by
upregulation of tissue factor (11). The effect of activating C5aR2
and C3aR are more diverse and the effect of activating these
receptors in the context of acute coronary syndromes (ACS) is
at present less clear.
IL-6 and complement may both contribute to the progression
of cardiovascular diseases (5, 12, 13) but there are limited data
on the interaction between these inflammatory proteins. In a
mouse sepsis model, IL-6 inhibition reduced the expression
of tissue C5aR (14), but to the best of our knowledge
the effects of IL-6 inhibition on the anaphylatoxin receptor
expression in human CAD have not been investigated. In a
recent study, the IL-6 receptor (IL-6R) antagonist tocilizumab
reduced C-reactive protein (CRP) and percutaneous coronary
intervention (PCI)-related troponin T (TnT) release in patients
with non-ST-elevation myocardial infarction (NSTEMI) (15).
In the present study, we aimed to investigate the expression
of the anaphylatoxin receptors in a sub-group of this patient
cohort (15). Additionally, anaphylatoxin receptor expression was
investigated in samples from patients with different entities of
CAD before any intervention was initiated.
MATERIALS AND METHODS
In this study we included two different patient cohorts: one
cohort consisting of NSTEMI-patients randomized to anti-
inflammatory treatment with an IL-6R antagonist or placebo
where blood was sampled from inclusion, before treatment and
with repeated measurements, and another cohort consisting of
patients with different entities of CAD where blood samples
were drawn at hospital admission, before treatment was
given.
NSTEMI Patients Treated With Tocilizumab
The present work is a sub-study of a previously published
double-blind, placebo-controlled two-center study on patients
(n = 117) admitted with NSTEMI randomized to treatment
with the IL-6R inhibitory monoclonal antibody tocilizumab
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(n = 58) or placebo (n = 59) (ClinicalTrails.gov, NCT01491074)
(15). Tocilizumab was administrated as a single dose of 280mg
immediately prior to coronary angiography. This dose provides
a complete IL-6 blockade for approximately 2 weeks (15).
Briefly, patients between 18 and 80 years of age with NSTEMI
scheduled for coronary angiography were included. Exclusion
criteria were clinically significant cardiac disease other than CAD,
disease or medication affecting inflammation, contraindications
to the treatment drug and clinically unstable patients. Patients
were included at a median of 2 days after symptom onset.
There were no significant between-group differences in baseline
characteristics (15). Fifteen age and sex-matched healthy controls
were included. A flow chart describing the whole patient
population randomized to tocilizumab or placebo and the
number of patients with or without PCI, and with early (≤2 days)
vs. late (>2 days) inclusion after symptoms onset is shown in
Figure 1.
We evaluated the expression of anaphylatoxin receptors
(C5aR1, C5aR2, and C3aR) in 60 of the patients treated with
tocilizumab (n = 28) or placebo (n = 32). These patients
represent all patients included at one of the two study centers (St.
Olavs hospital). Due to lack of resources, we only investigated
patients from half of the original study population. In this
subgroup of patients, there was a significant difference in gender,
but no other differences in baseline characteristics were found
(Table 1). The whole study population (n = 117) was included
for plasma complement activation analysis.
Patients With Various CAD Entities
Three patient groups with different entities of CAD, described
in detail elsewhere (16), were examined with respect to
anaphylatoxins receptor expression in blood samples obtained
at admission to hospital. CAD was defined as coronary artery
stenosis >50% verified by coronary angiography. The three
patient entities were defined as: (i) stable angina pectoris (SAP)
(n= 22), defined as episodes with reversible ischemic chest pain,
referred to elective coronary angiography. (ii) Non-ST-elevation
acute coronary syndromes (NSTE-ACS) that included unstable
angina and NSTEMI patients (n = 21), defined as angina at rest
or crescendo angina, referred to urgent coronary angiography
within 48 h. (iii) STEMI (n= 20) defined as elevated plasma levels
of Troponin T (TnT; at least one value above the 99th percentile)
together with ischemic symptoms and ST-segment elevation or
new left bundle branch block in the electrocardiogram referred
to immediate coronary angiography and PCI if indicated (16).
Patients that had malignant or chronic inflammatory diseases,
intercurrent infections, or were treated with glucocorticosteroids
were not included. Age and sex-matched healthy controls
(n= 29) were also included.
Blood Sampling Protocol
NSTEMI Tocilizumab Study
Blood samples drawn at the time of inclusion, i.e., before study
medicine was given and angiography performed, at day 2 and
3 following inclusion and after 6 months were included in this
sub-study. Blood was collected in EDTA vacutainer tubes (BD
Biosciences, Plymouth, UK), kept on crushed ice and centrifuged
within 30min at 2,500 g for 20min at 4◦C. Plasma was stored
at −80◦C until analyzed, and samples were thawed only once.
Whole blood (3mL) was collected in Tempus Blood RNA tubes
(ThermoFischer, Paisley, UK) from patients and healthy controls
ensuring immediate lysis of all blood cells and stabilization of
RNA. Tempus Blood RNA tubes were stored at−80◦C until RNA
preparation.
FIGURE 1 | Flow chart showing the total number of patients and randomization to tocilizumab and placebo groups. (A) Number in each group with or without PCI.
(B) Number in each group included early (≤2 days) or late (>2 days) from the onset of symptoms. NSTEMI, non-ST-elevated myocardial infarction.
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TABLE 1 | Clinical and biochemical characteristics of the study population 1
(n = 60).
Characteristics Placebo Tocilizumab p-value
Total number, n 32 28
Male sex, n (%) 32 (100) 23 (82) 0.02
Age, years, mean (SD) 59 (9) 58 (6) 1.00
Body mass index, kg/m2, median
(IQR)
27 (25, 29) 28 (27, 30) 1.00
Hypertension, n (%) 10 (31) 15 (54) 0.12
Diabetes mellitus, n (%) 5 (16) 5 (18) 1.00
Previous myocardial infarction,
n (%)
5 (16) 3 (11) 0.70
Current smoking, n (%) 13 (41) 9 (32) 0.60
Systolic blood pressure, BL,
mmHg (SD)
135 (14) 138 (17) 1.00
Diastolic blood pressure, BL,
mmHg (SD)
82 (11) 83 (10) 1.00
PCI, n (%) 23 (72) 21 (75) 1.00
LMWH BL, n (%) 29 (91) 26 (93) 1.00
CRP, BL, mg/L, median (IQR) 2.2 (0.7, 7.9) 3.3 (1.2, 6.7) 1.00
Troponin-T, BL, ng/L, median (IQR) 187 (87, 485) 107 (630) 1.00
Creatinine, BL, µmol/L, median
(IQR)
77 (71, 90) 75 (63, 89) 1.00
Peak CRP, mg/L, median (IQR) 5.4 (1.2, 8.3) 5.4 (1.4, 18.7) 1.00
Peak Troponin-T, ng/L, median
(IQR)
242 (92, 836) 128 (66, 937) 1.00
Peak Creatinine, µmol/L, median
(IQR)
86 (74, 93) 81 (71, 95) 1.00
Data are given as mean with (standard deviation, SD) or median with (25 and 75th
percentile, IQR) and number with (%). BL, baseline values; PCI, percutaneous coronary
intervention; LMWH, lowmolecular heparin administered before baseline; CRP, C-reactive
protein; R, receptor. Bold value indicate statistical significance.
Patients With Different CAD Entities and Healthy
Controls
Venous blood was drawn from healthy controls and patients
with SAP and NSTE-ACS before angiography. Arterial blood
was drawn from the arterial cannula immediately before
coronary angiography in patients with STEMI. Peripheral blood
mononuclear cells (PBMCs) were isolated from heparinized
blood in all three patient groups and the healthy controls by
Isopaque-Ficoll (Lymphoprep, FreseniusKabi Norge AS, Oslo,
Norway) gradient centrifugation within 1 h after sampling, stored
at−80◦C as cell pellets until RNA isolation was performed.
RNA Isolation and Quantitative PCR (qPCR)
NSTEMI Tocilizumab Study
Whole blood RNA purification was performed by Aaros Applied
Biotechnology, Aarhus, Denmark. mRNA from the healthy
controls was isolated using Tempus Spin RNA isolation Kit
(ThermoFischer, Paisley, UK). cDNA was produced using the
high capacity cDNA reverse transcriptase kit (Applied Biosystem,
Foster City, CA). TaqMan qPCR primers (FAM-MGB dye-
labeled) were purchased from Applied Biosystems for the
following genes: C5aR1 (HS00704891), C5aR2 (Hs01933768)
and C3aR (Hs0026963). Beta-2-microglobulin (HS 00187842)
was stably expressed and used as endogenous control. Each
sample was analyzed in triplicate and the reaction was run in 96
well-MicroAmp optical reaction plate on a StepOnePlus system
(Applied Biosystems).
Patients With Different CAD Entities
RNA from PBMC was isolated using RNeasy Mini Kit (Qiagen,
Hilden, Germany). cDNA was synthesized using qScript cDNA
SuperMix (Qantabio, BeverlyMA). SybrGreen primers were used
for qPCR (primer sequences can be given upon request) with
GAPDH as endogenous control. Each sample was analyzed in
duplicate in 384 well-optical reaction plate on a 7900 HT Fast
Real-time PCR system.
Complement Activation
Plasma complement activation was evaluated by quantification
of the terminal complement complex (TCC) in its soluble form
(sC5b-9) using an enzyme-linked immunosorbent assay (ELISA)
previously described in detail (17). Briefly, the mAb, aE11,
which binds to a neoepitope exposed in C9 when incorporated
into the C5b-9 complex, was used as capturing antibody and
a biotinylated monoclonal anti-C6 (clone 9C4) was used for
detection. The level was related to the International Complement
Standard #2, defined to contain 1,000 complement arbitrary units
(CAU) per mL (17).
Data Presentation and Statistical Analysis
Statistical analysis was performed with IBM SPSS Statistics 24
(Armonk, NY) or Graph Pad Prism, version 7 (San Diego,
CA). Differences between two groups were tested with t-test
or Mann-Whitney U test when the data were not normally
distributed. Differences between more than two groups were
tested with ordinary one-way ANOVA or with Kruskal-Wallis
test dependent on distribution. Change from baseline was
calculated for each time point (e.g., time point-baseline).
Longitudinal data were analyzed with Friedman test followed by
Wilcoxon signed-rank test to compare the specific time point
with baseline levels within each treatment group. To compare
differences in categorical data between groups the Chi-square test
was used. Correlation analysis was measured by the Spearman
correlation test. Bonferroni correction was used to correct for
multiple testing. Results are given as median with interquartile
range or mean with 95% confidence interval (CI). All tests were
two-sided and a p-level of <0.05 was regarded as statistically
significant.
Ethics
Both studies were approved by the Regional Committee for
Medical and Health Research Ethics of South-Eastern Norway
and the tocilizumab study also by The Norwegian Medicine
Agency and both studies were conducted in accordance with
the Declaration of Helsinki. All participants provided written
informed consent.
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RESULTS
The Effect of IL-6R Inhibition on
Anaphylatoxin Receptor Expression in
Whole Blood From NSTEMI Patients
C5aR1
Expression of C5aR1 was significantly lower in the tocilizumab
group compared to the placebo group at day 2 and 3 (Figure 2A).
Compared to baseline and the healthy controls, the expression of
C5aR1 at day 2 and 3 was significantly lower in the tocilizumab
group, whereas no difference was observed for the placebo group.
After 6 months the expression of C5aR1 in the tocilizumab group
was still significantly lower compared to baseline, which was not
the case for the placebo group. Compared to healthy controls
there was no difference at baseline or after 6 months in any of
the two patient groups (Figure 2A).
C5aR2
Expression of C5aR2 was significantly lower in the tocilizumab
group compared to the placebo group at day 2 and 3 (Figure 2B).
Compared to baseline levels, the expression of C5aR2 was
significantly lower in the tocilizumab group at day 2 and 3,
whereas no such difference was observed in the placebo group.
There were no differences between the two patients groups
at baseline or after 6 months. Compared to healthy controls,
C5aR2 expression was significantly decreased in the tocilizumab
group and the placebo group during the whole study period
(Figure 2B).
C3aR
C3aR expression behaved strictly different from the C5a
receptors. There were no differences in receptor expression
between the tocilizumab group and the placebo group at any
FIGURE 2 | Effect of tocilizumab on the expression of C5aR1, C5aR2, and C3aR in NSTEMI patients. The effect of tocilizumab, a monoclonal antibody inhibiting
interleukin 6 receptor (IL-6R), on the expression of the three complement anaphylatoxin receptors [C5aR1 (A), C5aR2 (B), and C3aR (C)] was investigated in patients
with non-ST-elevation myocardial infarction (NSTEMI). mRNA levels were quantified by qPCR and related to the reference gene beta-2-microglobulin. The tocilizumab
group (gray bars, n = 28) and the placebo group (white bars, n = 32) are presented at four different time-points. Baseline levels show the receptor expression at
inclusion, i.e., after hospital admission, before treatment was given. Follow-up time points were day 2 and 3, and 6 months. A group of healthy individuals (n = 15)
were included as controls. The qPCR results were quantified using the 2−11CT method, normalized to reference genes and presented as fold change with the
healthy controls as calibrator. Data are given as median and 95% CI. *P < 0.05, ***P < 0.001 vs. healthy controls. †P < 0.05, †††P < 0.001 differences in change
from baseline between tocilizumab and placebo. §p < 0.05, §§§p < 0.001 vs. baseline.
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of the time points (Figure 2C). In the tocilizumab group there
was a significantly higher expression of C3aR at day 2 and 3
when compared to baseline, whereas both patients groups had
significantly higher levels at day 2 and 3 compared to healthy
controls (Figure 2C). At baseline and after 6 months, there were
no differences in C3aR expression between the patient groups
and health controls (Figure 2C).
Effects of Coronary Intervention and Time
From Symptom Onset to Inclusion on the
Expression of Anaphylatoxin Receptors
The effect of tocilizumab could potentially depend on whether
the patients were treated with PCI or not, or whether they
were included early (≤2 days) or late (>2 days) from the
onset of symptoms. However, the pattern of the C5aR1, C5aR2
and C3aR expression was virtually identical in patients with or
without PCI (Figures 3A–C) and in patients included early or late
(Figures 3D–F). A flow chart of the patients is shown in Figure 1.
Systemic Complement Activation in
NSTEMI Patients
To see if inhibition of IL-6R affected complement activation,
sC5b-9 was evaluated in all patients in the tocilizumab study
(n = 117) from baseline to day 3, and at 6 months follow up.
Plasma concentration of sC5b-9 did not change over time in
the NSTEMI patients (Figure 4A). Tocilizumab had no effect on
the degree of systemic complement activation. The same pattern
was seen regardless of PCI treatment or not (Figure 4B) and
independent of early (≤2 days) or late (>2 days) inclusion from
the onset of symptoms (Figure 4C).
Association Between the Expression of
Anaphylatoxin Receptors and Key
Biomarkers in the NSTEMI Patients During
Hospitalization
The original tocilizumab study found a fall in leukocytes
in the tocilizumab-group, primarily caused by a decrease in
FIGURE 3 | Effect of coronary intervention and time of inclusion on the expression of C5aR1, C5aR2, and C3aR in NSTEMI patients. Expression level of complement
anaphylatoxin receptors C5aR1 (A,D), C5aR2 (B,E), and C3aR (C,F) in patients with non-ST-elevation myocardial infarction (NSTEMI) receiving placebo (n = 32) or
tocilizumab (n = 28) divided into two groups according to percutaneous coronary intervention (PCI) (23 placebo and 21 tocilizumab, gray bars) or not (7 placebo and 9
tocilizumab, white bars) (A–C), and divided into two groups according to inclusion ≤2 days (22 placebo and 15 tocilizumab, gray bars) or >2 days (10 placebo and 13
tocilizumab, white bars) from symptom onset (D–F). Baseline levels show the receptor expression at inclusion, i.e., after hospital admission, before treatment was
given. Follow-up time points were day 2 and 3, and 6 months. A group of healthy individuals (n = 15) were included as controls. The qPCR results were quantified
using the 2−11CT method, normalized to reference genes and presented as fold change with the healthy controls as calibrator. Data are given as median and 95%
CI. *P < 0.05, **P < 0.01, ***P < 0.001 vs. healthy controls. †P < 0.05, †††P < 0.001 differences in change from baseline between tocilizumab and placebo.
§p < 0.05, §§p < 0.01, §§§p < 0.001 vs. baseline.
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FIGURE 4 | Systemic complement activation in NSTEMI patients treated with tocilizumab or PCI. Complement activation, as evaluated by plasma sC5b-9, is shown
for NSTEMI patients (total n = 117) treated with tocilizumab (n = 58; closed circles) or placebo (n = 59; open circles) (A). Complement activation, as evaluated by
plasma sC5b-9, is shown for the same population of NSTEMI patients further divided into two groups according to percutaneous coronary intervention (47 placebo
and 41 tocilizumab) or not (12 placebo and 17 tocilizumab) (B), and according to inclusion ≤2 days (36 placebo and 30 tocilizumab) or >2 days (23 placebo and 28
tocilizumab) from symptom onset to inclusion (C). The dotted line represents normal upper level of sC5b-9 in healthy blood donors. Data are given as mean and 95%
CI. ††P < 0.01, †††P < 0.001 differences in change from baseline between tocilizumab and placebo. §p < 0.05, §§p < 0.01, §§§p < 0.001 vs. baseline.
neutrophils from baseline to day 3 which led to a significant
between-group difference in change from baseline (15). The
same statistical differences were also found in the sub-group
of patients studied here (Table 2). We found no correlation
between change in neutrophils and change in expression level
of any of the three anaphylatoxin receptors in the treatment
group (Supplementary Table 1). However, in the placebo group
there was a significant correlation between change in neutrophils
and change in the expression level of C5aR1 and C5aR2
(Supplementary Table 1).
In the original tocilizumab study, IL-6 and sIL-6R increased
significantly from baseline to day 3 in the tocilizumab-
treated patients (15). A similar pattern was found in the
sub-group of patients investigated in this study (Table 2).
In the tocilizumab group no correlation was found between
change in expression for any of the anaphylatoxin receptors
and IL-6 in the tocilizumab. sIL-6R correlated with the
expression of C3aR in the tocilizumab-treated patients
(Supplementary Table 1). In the placebo group we found
a significant correlation between all three anaphylatoxin
receptors and IL6 whereas no correlation was found for sIL-6R
(Supplementary Table 1).
Associations Between the Anaphylatoxin
Receptors and CRP and TnT in the NSTEMI
Patients During Hospitalization
We evaluated whether AUC for the three anaphylatoxin
receptors showed any correlation with AUC for CRP and
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TnT representing the primary and most important secondary
endpoint, respectively, in the original tocilizumab study (15)
(Table 3). There was a significant correlation between C5aR1 and
C3aR, but not C5aR2, and CRP in the placebo group, whereas
only C3aR was correlated with CRP in the tocilizumab group
(Table 3; Supplementary Figure 1). TnT correlated significantly
with all three receptors in the placebo group, whereas only
C5aR1 correlated with TnT in the tocilizumab group (Table 3;
Supplementary Figure 1). All correlations between receptor
expression and CRP and TnT were positive. The regression
plots, however, show negative regression lines since the
statistics were calculated on delta-CT values and a decrease
in the delta-CT value represents an increase in receptor
expression.
Expression of Anaphylatoxin Receptors in
PBMC From Patients With Different CAD
Entities
In order to explore whether the expression of anaphylatoxin
receptors is dependent on the severity of CAD, independent
TABLE 2 | Baseline values and values at day 3 for different relevant biomarkers in
the NSTEMI patients.
Group Baseline Day 3
IL-6 pg/mL Placebo 3.0 (1.2–5.1) 3.2 (1.7–6.3) †
Tocilizumab 2.4 (1.3–4.5) 22(14.3–29)***
sIL-6R ng/mL Placebo 71 (13) 70 (11) †††
Tocilizumab 64 (11) 88 (8.4)
Leukocytes (109/L) Placebo 7.6 (1.7) 7.6 (1.3) †††
Tocilizumab 8.0 (2.4) 4.9 (1.6)
Neutrophils (109/L) Placebo 4.5 (3.3–5.7) 4.3 (3.7–5.2) †††
Tocilizumab 5.1 (3.2–6.0) 1.9 (1.2–2.7)
Monocytes (109/L) Placebo 0.7 (0.2) 0.7 (0.6–0.9)
Tocilizumab 0.7 (0.5–0.9) 0.6 (0.2)
Lymphocytes (109/L) Placebo 2.0 (0.5) 2.1 (0.6)
Tocilizumab 2.0 (0.7) 1.9 (1.6–2.5)
Data are given as mean with (standard deviation, SD) or median with (25 and 75th
percentile, IQR). IL, interleukin; R, receptor; s, soluble.
***p < 0.001 comparing differences within group from baseline.
†p < 0.05, †††p < 0.001 comparing between-group differences in change from baseline.
TABLE 3 | Spearman Rho correlation between AUC during hospitalization for
CRP and TnT and the three anaphylatoxin receptors in the NSTEMI patients.
AUC AUC AUC
C5aR1 C5aR2 C3aR
AUC CRP Placebo 0.431* 0.214 0.506**
Tocilizumab 0.264 0.082 0.338
AUC TnT Placebo 0.399* 0.494** 0.400*
Tocilizumab 0.534* 0.315 0.259
AUC, area under the curve; TnT, troponin T; CRP, C-reactive protein; R, receptor.
Data: Spearman Rho correlation coefficient with *p < 0.05, **p < 0.01. Bold values
indicate statistical significance.
on any intervention, we investigated the expression of these
receptors in PBMCs in samples obtained from patients admitted
to hospital comprising three different entities of CAD: SAP
(n= 22), NSTE-ACS (n= 21), and STEMI (n= 20).
Whereas C5aR1 expression was significantly increased in all
CAD subgroups compared to healthy controls with the highest
levels in the STEMI patients (Figure 5A), the increase in C5aR2
and C3aR were more moderate, showing significantly increased
levels as compared with controls in the STEMI group (C5aR2)
and NSTE-ACS group (C3aR) only (Figures 5B,C).
DISCUSSION
This study demonstrates for the first time that inhibiting IL-
6R profoundly attenuated the expression of C5aR1 and C5aR2
in peripheral whole blood in NSTEMI patients. Treatment with
PCI is known to cause a reperfusion injury, which in itself can
enhance inflammation. However, the effect on the anaphylatoxin
receptor expression seen in this study was independent of
treatment with PCI or time between debut of symptoms and
inclusion. In contrast, C3aR expression was not affected by
the IL-6-inhibitory treatment. Moreover, changes in C5aR1 was
significantly correlated with changes in TnT during tocilizumab
treatment suggesting the beneficial effect of IL-6R inhibition at
least partly could involve downregulation of the inflammatory
C5aR1.
Inflammation plays a pivotal role in the wake of a MI being
essential for cardiac repair (18). However, sustained and excessive
inflammation may contribute to increased tissue damage and is
associated with worse prognosis in ACS (19). Elevated levels of
inflammatory markers like CRP, IL-6 and C5a are related to the
detrimental effects of inflammation in CAD (5, 13, 19–22) and
anti-inflammatory treatment is suggested to improve outcome
after MI (23). Genetic studies suggest that inhibiting either IL-
6 or complement could prove beneficial in patients with CAD
(24–26), and it has recently been shown that a single dose of
tocilizumab attenuates the increase in CRP and PCI-related TnT
release in NSTEMI patients (15).
The activation of C5aR1 induces pro-inflammatory effects like
recruitment and activation of inflammatory cells and enhanced
cytokine and chemokine production. Experimental studies have
shown reduction in infarct size and inflammation when the
C5a/C5aR1-axis has been attenuated (27–30). Furthermore, lack
of C5aR1 on circulating leukocytes led to reduced infarct size
and improved clinical outcome in an in vivo mouse model
of MI (31). IL-6 inhibition is previously shown to attenuate
expression of anaphylatoxin receptors in an experimental
model of sepsis (14). Herein, we show a similar pattern in
NSTEMI patients with a significant downregulation of C5Ra1
by tocilizumab in the first days following NSTEMI. Notably, this
downregulation was significantly correlated with TnT release in
the tocilizumab group suggesting that downregulation of C5aR1
might contribute to the attenuated TnT release by tocilizumab
seen in these patients (15). The gradual increase in C5aR1
expression in the different CAD subgroups from SAP through
NSTE-ACS with the highest level in STEMI patients may further
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FIGURE 5 | Expression of C5aR1, C5aR2 and C3aR in patients with various
entities of CAD. Expression of the C5aR1 (A), C5aR2 (B), and C3aR (C) in
three different patients groups with verified coronary artery disease (CAD):
stable angina pectoris (SAP, n = 22), non-ST-elevation acute coronary
syndromes (NSTE-ACS, n = 21) and ST-elevation myocardial infarction
(STEMI, n = 20). A group of healthy age and sex-matched individuals were
included as controls (Ctrls, n = 29). mRNA levels were quantified by qPCR
using the 2−11CT method, normalized to reference genes (GAPDH) and
presented as fold change with the healthy controls as calibrator. Data are given
as median and 95% CI. Statistical significant differences are indicated between
the patient populations and the healthy controls. *p < 0.05, **p < 0.01,
***p < 0.001 vs. healthy controls.
support a role for this receptor in plaque progression and
destabilization.
C5aR2, previously considered a non-signaling receptor, has
been shown to have both pro- and anti-inflammatory effects and
its function seems to be dependent on cell type, disease context
and species (32). In experimental studies of CAD, there is some
evidence that antagonizing C5aR2 might have beneficial effects
(9). In the present study we showed a downregulation of C5aR2
by tocilizumab in NSTEMI patients. However, changes in C5aR2
were not correlated with changes in TnT during tocilizumab
treatment, and in contrast to C5aR1 expression, the changes in
C5aR2 expression in PBMC in the different CAD subgroups were
rather modest.
In the NSTEMI patient group, a reduction in C5aR2
expression was observed both in the tocilizumab group and
the placebo group, throughout the whole study period. The
expression of C5aR2 is known to be attenuated in the context
of inflammation (33) and the reduced level of C5aR2 in both
the placebo group and the tocilizumab group even observed at
inclusion might be due to the inflammatory response caused
by the MI itself. We did not find the same reduction in C5aR2
expression compared to controls in the PBMC CAD group. The
reason for this is unknown, but might be due to differences in
time of sampling in relation to the myocardial injury, different
expression level in different cell types or different methods. The
effect on C5aR2 seen after 6 months might be related to the
enhanced inflammation caused by the reperfusion injury caused
by treatment with PCI. Also attenuating IL-6, which is a pleiotrop
cytokine, might indirectly change the expression of C5aR2. Thus,
the effects of C5aR2 in the setting of CAD and myocardial
damage are still unclear and needs further investigations.
C3aR was previously regarded as a pro-inflammatory receptor
but recent studies support a more complex effector function for
this receptor with anti-inflammatory effects in the acute phase
of inflammation by preventing neutrophil mobilization from
the bone marrow (34). In an experimental study of intestinal
ischemia and reperfusion injury, C3aR was shown to ameliorate
ischemia-reperfusion injury in mice (35). Herein, we found a
marked increase in C3aR expression in NSTEMI patients that
was not modulated by tocilizumab. Moreover, C3aR, but not the
two C5a receptors, correlated positively with changes in CRP
during IL-6 receptor inhibition. Whatever the effect of C3aR,
these findings suggest that IL-6 differently affect the expression
of the C5a receptors and C3aR.
There was a reduction in the number of leukocytes and
particularly neutrophils in the tocilizumab-treated NSTEMI
patients as demented in the original study (15). This could,
however, not explain the decreased C5aR1 and C5aR2 expression.
First, there was no correlation between the change in receptor
expression and change in neutrophil levels in the tocilizumab
group. Second, the amount of mRNA in all samples was identical
coming mainly from granulocytes, lymphocytes and monocytes,
which constitute themain amount of nucleated cells in peripheral
blood. Also lymphocytes and monocytes express anaphylatoxin
receptors. Lymphocytes have previously been found to express
C5aR1 (36–39) and the two C5a-anaphylatoxin receptors are
typically co-expressed (33). Monocytes also express all three
anaphylatoxin receptors shown for the CAD-population in this
study. Third, the decrease was explicitly seen for the C5a
receptors and not for the C3aR, indicating that the decrease
was selective. Taken together this supports a real reduction in
expression of C5aR1 and C5aR2.
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In the present study, we used whole blood and PBMC,
precluding us for detecting individual cell populations as would
have been possible using cell sorting. There is, however, an
advantage of using whole blood for this purpose, since the cells
are less manipulated and in vitro changes in cell activity is
reduced and the changes are to a greater extent reflecting the
in vivo situation.
No correlation between IL-6 or sIL-6R and the three different
anaphylatoxin receptors in the tocilizumab-treated patients, were
observed. Tocilizumab was administrated in doses high enough
to give a total IL-6 blockade for about 2 weeks (15) thus the
level of IL-6 or sIL-6R is rather irrelevant since the effect of the
cytokine is totally blocked in all patients during the hospital stay.
We did find a correlation between the anaphylatoxin receptors
and IL-6 and sIL-6R in the in the placebo group consistent with
rather little change in both IL-6 and the anaphylatoxin receptors
during the time course in this group.
sC5b-9 did not increase in the present study which most likely
was due to the relatively small MIs in the NSTEMI patients.
Complement is however constantly activated at a low level and
acts in the circulation as a humoral alarm system ready to respond
to any danger threatening the host (40). Importantly, the absence
of significant systemic complement activation does not preclude
the presence of local activation with the ability to act at the site
of damage. Thus, downregulation of the receptors for C5a might
have beneficial effects both locally and systemically.
The present study has some limitations. The number of
patients was rather low. Also, the lack of protein data on the
anaphylatoxin receptor expression may weaken our conclusions.
Finally, it should be emphasized that correlations do not
necessarily mean any causal relationship and more mechanistic
studies are needed to further explore the role of anaphylatoxin
receptors in CAD.
In conclusion, a substantial and statistically highly significant
reduction of C5a receptors was observed in NSTEMI patients
treated with tocilizumab, and as for C5aR1, the downregulation
correlated with attenuated TnT release. C5aR1 expression in
PBMC did also reflect disease severity in another separate
CAD population. The cross-talk between complement
C5aR1 and IL-6 might contribute to the attenuated TnT
release during tocilizumab treatment in these NSTEMI
patients.
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